Why HCA Healthcare, Inc. (HCA) stock moved
HCA Healthcare, Inc. (HCA) shares fell 3.8% to $371.18 as of July 20, 2026, a moderate decline from the prior close of $385.74. BestStocks flagged the session as a material change for HCA. Below, we break down what changed for HCA, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
HCA fell 3.8% to $371.18
HCA fell 3.8% in its latest session, moving from $385.74 to $371.18.
What it means for HCA Healthcare, Inc. investors
For HCA Healthcare, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: HCA Healthcare, Inc. (HCA) moved +4.19% from $363.60 to $378.85 on July 15, 2026; Positive price momentum. Weighing against that: Negative session, down 3.8%; HCA Healthcare, Inc. (HCA) moved −3.77% from $385.74 to $371.18 on 2026-07-17. Wall Street's consensus price target sits at $486.85, implying +31.2% upside from $371.18. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 4 days out, the next report is the most likely near-term test of the move.
HCA price reaction
HCA last traded at $371.18, down $14.56 (-3.77%) from the previous close of $385.74. The session traded on 0.8× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $363.60 and $423.11, and it currently sits about 13% of the way up that band.
Bullish and bearish analyst opinions on HCA Healthcare, Inc. (HCA)
The consensus analyst price target on HCA Healthcare, Inc. (HCA) is $486.85, 31.2% above the recent $371.18. Over the past 90 days analysts logged 0 upgrades, 15 maintains, and 1 downgrade. Here is how the bullish and bearish cases on HCA line up.
The bullish case
- Wall Street's consensus price target of $486.85 implies +31.2% upside from $371.18.
- The Street's most bullish target is $635.00 (+71.1%).
- HCA Healthcare, Inc. (HCA) moved +4.19% from $363.60 to $378.85 on July 15, 2026.
- Positive price momentum.
The bearish case
- 1 analyst downgrade in the past 90 days, most recently Barclays to Equal Weight (2026-07-08).
- Negative session, down 3.8%.
- HCA Healthcare, Inc. (HCA) moved −3.77% from $385.74 to $371.18 on 2026-07-17.
- HCA moved -2.95% from $423.11 to $410.61 on 2026-07-08.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for HCA
Frequently asked questions about HCA
Why did HCA Healthcare, Inc. (HCA) stock move?
HCA fell 3.8% to $371.18. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did HCA stock fall?
HCA lost 3.77% ($14.56) versus the prior close of $385.74, last trading at $371.18 on 0.8× average volume.
When is HCA Healthcare, Inc.'s next earnings date?
HCA's next earnings report is estimated for 2026-07-24 — about 4 days away.
What is the analyst price target for HCA?
The consensus analyst price target for HCA is $486.85, about 31.2% above the current $371.18. Over the past 90 days, analysts recorded 0 upgrades, 15 maintains, and 1 downgrade.
How BestStocks tracks HCA
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared HCA-specific materiality thresholds, triggering an evidence check. It draws on 11 tracked change events for HCA, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.